Management of cancer treatment-related diarrhea: Issues and therapeutic strategies

Steven Kornblau*, Al B Benson III, Robert Catalano, Richard E. Champlin, Constance Engelking, Michael Field, Cindy Ippoliti, Hillard M. Lazarus, Edith Mitchell, Joseph Rubin, Patrick J. Stiff, Everett Vokes, Scott Wadler

*Corresponding author for this work

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The cancer treatment-related diarrhea caused by acute graft-versus-host disease (GVHD) and chemotherapeutic agents, particularly fluoropyrimidines and irinotecan, significantly affects patient morbidity and mortality. The mechanisms causing cancer treatment-related diarrhea are not fully understood, but histopathologic evidence points to a multifactorial process that causes an absorptive and secretory imbalance in the small bowel. Cancer treatment-related diarrhea could be life-threatening, yet assessment and treatment are not currently standardized. Several clinicians participated in a closed roundtable meeting to review the mechanisms of chemotherapy-induced diarrhea (CID) and GVHD-induced diarrhea, management issues in cancer treatment-induced diarrhea, and pharmacologic approaches to treatment. The meeting produced a proposal for new treatment guidelines and an algorithm, which include the use of octreotide for the management of CID- and GVHD-induced diarrhea. The development of diarrhea assessment guidelines that expand on the current National Cancer Institute criteria and allow for better patient management was also proposed. Copyright (C) 2000 U.S. Cancer Pain Relief Committee.

Original languageEnglish (US)
Pages (from-to)118-129
Number of pages12
JournalJournal of Pain and Symptom Management
Volume19
Issue number2
DOIs
StatePublished - Jan 1 2000

Fingerprint

Second Primary Neoplasms
Diarrhea
Graft vs Host Disease
irinotecan
Therapeutics
Guidelines
Drug Therapy
Octreotide
National Cancer Institute (U.S.)
Morbidity
Mortality

Keywords

  • Bone marrow transplant
  • Diarrhea
  • Fluoropyrimidines
  • Graft-versus-host disease
  • Irinotecan
  • Octreotide

ASJC Scopus subject areas

  • Nursing(all)
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Kornblau, Steven ; Benson III, Al B ; Catalano, Robert ; Champlin, Richard E. ; Engelking, Constance ; Field, Michael ; Ippoliti, Cindy ; Lazarus, Hillard M. ; Mitchell, Edith ; Rubin, Joseph ; Stiff, Patrick J. ; Vokes, Everett ; Wadler, Scott. / Management of cancer treatment-related diarrhea : Issues and therapeutic strategies. In: Journal of Pain and Symptom Management. 2000 ; Vol. 19, No. 2. pp. 118-129.
@article{65c3a3d1f2674bf39a076648687bd9af,
title = "Management of cancer treatment-related diarrhea: Issues and therapeutic strategies",
abstract = "The cancer treatment-related diarrhea caused by acute graft-versus-host disease (GVHD) and chemotherapeutic agents, particularly fluoropyrimidines and irinotecan, significantly affects patient morbidity and mortality. The mechanisms causing cancer treatment-related diarrhea are not fully understood, but histopathologic evidence points to a multifactorial process that causes an absorptive and secretory imbalance in the small bowel. Cancer treatment-related diarrhea could be life-threatening, yet assessment and treatment are not currently standardized. Several clinicians participated in a closed roundtable meeting to review the mechanisms of chemotherapy-induced diarrhea (CID) and GVHD-induced diarrhea, management issues in cancer treatment-induced diarrhea, and pharmacologic approaches to treatment. The meeting produced a proposal for new treatment guidelines and an algorithm, which include the use of octreotide for the management of CID- and GVHD-induced diarrhea. The development of diarrhea assessment guidelines that expand on the current National Cancer Institute criteria and allow for better patient management was also proposed. Copyright (C) 2000 U.S. Cancer Pain Relief Committee.",
keywords = "Bone marrow transplant, Diarrhea, Fluoropyrimidines, Graft-versus-host disease, Irinotecan, Octreotide",
author = "Steven Kornblau and {Benson III}, {Al B} and Robert Catalano and Champlin, {Richard E.} and Constance Engelking and Michael Field and Cindy Ippoliti and Lazarus, {Hillard M.} and Edith Mitchell and Joseph Rubin and Stiff, {Patrick J.} and Everett Vokes and Scott Wadler",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S0885-3924(99)00149-9",
language = "English (US)",
volume = "19",
pages = "118--129",
journal = "Journal of Pain and Symptom Management",
issn = "0885-3924",
publisher = "Elsevier Inc.",
number = "2",

}

Kornblau, S, Benson III, AB, Catalano, R, Champlin, RE, Engelking, C, Field, M, Ippoliti, C, Lazarus, HM, Mitchell, E, Rubin, J, Stiff, PJ, Vokes, E & Wadler, S 2000, 'Management of cancer treatment-related diarrhea: Issues and therapeutic strategies', Journal of Pain and Symptom Management, vol. 19, no. 2, pp. 118-129. https://doi.org/10.1016/S0885-3924(99)00149-9

Management of cancer treatment-related diarrhea : Issues and therapeutic strategies. / Kornblau, Steven; Benson III, Al B; Catalano, Robert; Champlin, Richard E.; Engelking, Constance; Field, Michael; Ippoliti, Cindy; Lazarus, Hillard M.; Mitchell, Edith; Rubin, Joseph; Stiff, Patrick J.; Vokes, Everett; Wadler, Scott.

In: Journal of Pain and Symptom Management, Vol. 19, No. 2, 01.01.2000, p. 118-129.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Management of cancer treatment-related diarrhea

T2 - Issues and therapeutic strategies

AU - Kornblau, Steven

AU - Benson III, Al B

AU - Catalano, Robert

AU - Champlin, Richard E.

AU - Engelking, Constance

AU - Field, Michael

AU - Ippoliti, Cindy

AU - Lazarus, Hillard M.

AU - Mitchell, Edith

AU - Rubin, Joseph

AU - Stiff, Patrick J.

AU - Vokes, Everett

AU - Wadler, Scott

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The cancer treatment-related diarrhea caused by acute graft-versus-host disease (GVHD) and chemotherapeutic agents, particularly fluoropyrimidines and irinotecan, significantly affects patient morbidity and mortality. The mechanisms causing cancer treatment-related diarrhea are not fully understood, but histopathologic evidence points to a multifactorial process that causes an absorptive and secretory imbalance in the small bowel. Cancer treatment-related diarrhea could be life-threatening, yet assessment and treatment are not currently standardized. Several clinicians participated in a closed roundtable meeting to review the mechanisms of chemotherapy-induced diarrhea (CID) and GVHD-induced diarrhea, management issues in cancer treatment-induced diarrhea, and pharmacologic approaches to treatment. The meeting produced a proposal for new treatment guidelines and an algorithm, which include the use of octreotide for the management of CID- and GVHD-induced diarrhea. The development of diarrhea assessment guidelines that expand on the current National Cancer Institute criteria and allow for better patient management was also proposed. Copyright (C) 2000 U.S. Cancer Pain Relief Committee.

AB - The cancer treatment-related diarrhea caused by acute graft-versus-host disease (GVHD) and chemotherapeutic agents, particularly fluoropyrimidines and irinotecan, significantly affects patient morbidity and mortality. The mechanisms causing cancer treatment-related diarrhea are not fully understood, but histopathologic evidence points to a multifactorial process that causes an absorptive and secretory imbalance in the small bowel. Cancer treatment-related diarrhea could be life-threatening, yet assessment and treatment are not currently standardized. Several clinicians participated in a closed roundtable meeting to review the mechanisms of chemotherapy-induced diarrhea (CID) and GVHD-induced diarrhea, management issues in cancer treatment-induced diarrhea, and pharmacologic approaches to treatment. The meeting produced a proposal for new treatment guidelines and an algorithm, which include the use of octreotide for the management of CID- and GVHD-induced diarrhea. The development of diarrhea assessment guidelines that expand on the current National Cancer Institute criteria and allow for better patient management was also proposed. Copyright (C) 2000 U.S. Cancer Pain Relief Committee.

KW - Bone marrow transplant

KW - Diarrhea

KW - Fluoropyrimidines

KW - Graft-versus-host disease

KW - Irinotecan

KW - Octreotide

UR - http://www.scopus.com/inward/record.url?scp=0034000694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034000694&partnerID=8YFLogxK

U2 - 10.1016/S0885-3924(99)00149-9

DO - 10.1016/S0885-3924(99)00149-9

M3 - Article

C2 - 10699539

AN - SCOPUS:0034000694

VL - 19

SP - 118

EP - 129

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 2

ER -